TABLE 2

Effects of IL-6, LPS, and ANC28.1 on P450 mRNA expression and enzyme activities in human hepatocytes in vitro

TreatmentCultures Used in LPS Experiments (n = 3)Cultures Used in ANC28.1 Experiments (n = 3)
CYP1A2
 P450 mRNA (RQFa)
  Medium1.00 ± 0.00b1.00 ± 0.00
  IL-6 (10 ng/ml)0.831 ± 0.7910.280 ± 0.115
  LPS (25 ng/ml)0.617 ± 0.150NA
  ANC28.1 (2 μg/ml)NA1.17 ± 0.172
 P450 activity (% of control)
  Medium100% (value = 43.9 ± 12.8 ng/ml)c100% (value = 45.3 ± 21.6 ng/ml)
  IL-6 (10 ng/ml)34.7 ± 7.3130.3 ± 9.50
  LPS (25 ng/ml)45.9 ± 15.6NA
  ANC28.1 (2 μg/ml)NA85.2 ± 22.4
CYP2B6
 P450 mRNA (RQF)
  Medium1.00 ± 0.001.00 ± 0.00
  IL-6 (10 ng/ml)0.240 ± 0.1660.400 ± 0.170
  LPS (25 ng/ml)0.439 ± 0.0877NA
  ANC28.1 (2 μg/ml)NA1.09 ± 0.354
 P450 activity (% of control)
  Medium100% (value = 77.3 ± 30.3 ng/ml)100% (value = 55.2 ± 18.4 ng/ml)
  IL-6 (10 ng/ml)34.3 ± 1.4055.0 ± 24.5
  LPS (25 ng/ml)89.8 ± 61.9NA
  ANC28.1 (2 μg/ml)NA82.5 ± 21.3
CYP3A4
 P450 mRNA (RQF)
  Medium1.00 ± 0.001.00 ± 0.00
  IL-6 (10 ng/ml)0.00433 ± 0.004040.0667 ± 0.0808
  LPS (25 ng/ml)0.0230 ± 0.0283NA
  ANC28.1 (2 μg/ml)NA0.673 ± 0.454
 P450 activity (% of control)
  Medium100% (value = 477 ± 132 ng/ml)100% (value = 260 ± 26.6 ng/ml)
  IL-6 (10 ng/ml)16.6 ± 17.424.3 ± 1.70
  LPS (25 ng/ml)28.6 ± 11.2NA
  ANC28.1 (2 μg/ml)NA88.9 ± 19.0
  • NA, not applicable; RQF, relative quantification factor.

  • a RQF is a measure of a change in mRNA expression in a test sample relative to that in a control sample (e.g., medium).

  • b Values are the mean ± standard deviation of triplicate determinations of RQF.

  • c Values are the mean ± standard deviation of triplicate determinations of phenacetin O-dealkylation (CYP1A2), bupropion hydroxylation (CYP2B6), or midazolam 1´-hydroxylation (CYP3A) expressed as percent of control (medium alone).